Q-omics provides the consensus-scored ZNF562 profile across patient tissues and cancer cell-line models. ZNF562 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF562 is differentially expressed in 16, with the highest sampling consensus in LIHC. Additionally, ZNF562 RNA expression shows 21,198 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LIHC, and ACC as cancer lineages where ZNF562 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF562 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF562 survival associations across molecular data types. ZNF562 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF562 RNA expression–survival associations across cancer types. High ZNF562 expression shows unfavorable associations in KICH, ACC and LGG, but favorable associations in HNSC, COAD and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF562 RNA expression.
This table summarizes ZNF562 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF562. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF562 shows higher tumor expression in LIHC, HNSC, BLCA, UCEC, STAD and LUSC. The LIHC box plot shows higher ZNF562 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with ZNF562 in patient tissues and cancer cell lines. In patient samples, ZNF562 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF562 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
